Cognis Health & Nutrition (La Grange, IL) has exclusively licensed two new active ingredients for weight management and cognitive performance from InterMed Discovery (IMD; Dortmund, Germany).
Cognis Health & Nutrition (La Grange, IL) has exclusively licensed two new active ingredients for weight management and cognitive performance from InterMed Discovery (IMD; Dortmund, Germany).
Cognis says that both ingredients show promising benefits based on IMD’s testing, including in vivo tests. Cognis plans to conduct its own testing on the ingredients this year.
Cognis has already licensed four other ingredients from IMD for weight management and heart health. A clinical test on one of the four ingredients will begin later this year, while the other ingredients are in advanced preclinical testing and scale-up mode.
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
Synergistic blend of fructooligosaccharide and L-theanine supports memory in recent study
June 10th 2024A recent study found that the combination of fructooligosaccharide (FOS) and L-theanine, marketed as GBL-Memory from Green Bioactives, based in Edinburgh, Scotland was able to support memory in both animals and humans.